Earnings dates and session timing shown here are aggregated from third-party sources, are frequently estimated, and are subject to change or confirmation by the reporting company. Nothing on this site is financial advice.
MaxCyte Inc. (MXCT) is a leader in cell-engineering, renowned for its innovative Flow Electroporation® technology that enables efficient and scalable delivery of nucleic acids and proteins into a variety of cell types. The company serves a prestigious clientele, including top biopharmaceutical firms and research institutions, positioning it favorably within the rapidly expanding cell and gene therapy market. MaxCyte's advanced platforms play a crucial role in the development of novel cell-based therapies and vaccines, responding to the growing global demand for transformative healthcare solutions. With a steadfast commitment to enhancing patient outcomes, MaxCyte is poised to capitalize on significant market opportunities in the life sciences sector.
Quotes and fundamental data are delayed and provided for informational purposes only — nothing on this page is financial advice. Figures are as reported by the company and its data providers and may be revised. Estimates reflect analyst consensus at the time of each report.
$1.28
| Quarter | EPS | Revenue | Price move | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Est | Adj | Result | GAAP | Est | Actual | Surprise | 1D Pre | On-Day | 1D Post | |
Q ended Jun 30, 2026 Reported Aug 12, 2026 | $-0.12 | $-0.08 | Beat +33.3% | $-0.08 | $6.5M | $7.3M | +12.3% | 1D Pre+2.5% | On-Day+2.4% | 1D Post+9.4% |
Q ended Mar 31, 2026 Reported May 12, 2026 | $-0.06 | $-0.04 | Beat +33.3% | $-0.04 | $7.3M | $9.7M | +32.9% | 1D Pre-3.1% | On-Day+0.6% | 1D Post+24.1% |
Q ended Dec 31, 2025 Reported Mar 24, 2026 | $-0.07 | $-0.05 | ||||||||
Dashed outlines show the analyst consensus estimate for periods where one was published. Hover or tap a bar for exact figures. Values as reported; not adjusted for splits after the report date.
| — |
| $9.2M |
| $7.3M |
| -20.7% |
| 1D Pre-1.1% |
| On-Day-2.2% |
| 1D Post-6.8% |
Q ended Sep 30, 2025 Reported Nov 12, 2025 | $-0.11 | $-0.12 | Miss -9.1% | — | $8.5M | $6.8M | -20.0% | 1D Pre+5.4% | On-Day+1.9% | 1D Post-4.4% |